Table 1.

Factors associated with all-cause mortality and cancer-related mortality of patients with sarcoma

	All-cause mortality			Cancer-related mortality
	HR	95% CI	P value	HR	95% CI	P value
Male	1.123	(0.983 to 1.282)	0.087	1.008	(0.863 to 1.177)	0.921
Age group (<18, children and adolescent)
18 to <40, young adults	1.813	(1.293 to 2.542)	0.001*	2.040	(1.366 to 3.048)	<0.001*
40 to <65, adults	1.502	(0.927 to 2.435)	0.098	1.618	(0.936 to 2.798)	0.085
65 to <80, young elderly	1.945	(1.132 to 3.343)	0.016*	1.997	(1.075 to 3.711)	0.029*
≥80, elderly	2.685	(1.526 to 4.725)	0.001*	2.689	(1.403 to 5.154)	0.003*
Sarcoma tumour site (both)
Bone and articular cartilage	0.972	(0.698 to 1.355)	0.869	0.915	(0.625 to 1.339)	0.648
Connective and other soft-tissue	1.093	(0.801 to 1.493)	0.575	1.083	(0.759 to 1.544)	0.660
Charlson Comorbidity Index (2)
3	1.420	(0.955 to 2.112)	0.083	1.575	(1.017 to 2.442)	0.042*
4	1.672	(1.058 to 2.642)	0.028*	1.808	(1.091 to 2.997)	0.022*
5	1.878	(1.169 to 3.017)	0.009*	1.908	(1.125 to 3.236)	0.016*
6	2.337	(1.418 to 3.853)	0.001*	2.275	(1.298 to 3.987)	0.004*
≥7	2.391	(1.441 to 3.969)	0.001*	2.143	(1.210 to 3.799)	0.009*
Abnormal NLR*	1.698	(1.424 to 2.025)	<0.001*	1.648	(1.341 to 2.025)	<0.001*
Abnormal PLR*	1.346	(1.164 to 1.555)	<0.001*	1.430	(1.205 to 1.697)	<0.001*
Abnormal serum LDH*	1.355	(1.182 to 1.554)	<0.001*	1.302	(1.108 to 1.529)	0.001*
Chemotherapy ever used (not ever used)
Anthracyclines not ever used	1.511	(1.270 to 1.797)	<0.001*	1.567	(1.282 to 1.917)	<0.001*
Anthracyclines-based chemotherapy as first line	1.511	(1.249 to 1.828)	<0.001*	1.560	(1.255 to 1.941)	<0.001*
Non-anthracyclines as first line but anthracyclines ever used	1.547	(1.101 to 2.174)	0.012*	1.799	(1.238 to 2.614)	0.002*

*Abnormal NLR: NLR ≥2.5; abnormal PLR: PLR ≥182; abnormal Serum LDH: <106 or >218 (for men); <103 or >199 (for women).

LDH, lactate dehydrogenase; NLR, neutrophil-lymphocyte ratio; PLR, platelet-lymphocyte ratio.